Ethylmorphine

Sources

1 strong · 15 moderate · 4 weak

Studies and references cited across this article, graded by evidence strength.

Values approved

95/95 (100%)

Data points an editor reviewed and accepted for publication.

Value Provenance

Dosing

oraltrace

Field	Published	AI Proposed	Confidence
Threshold	20 mg	20 mg	low
Low	40–50 mg	40–50 mg	low
Common	50–100 mg	50–100 mg	low
Strong	100–200 mg	100–200 mg	low
Heavy	200+ mg	200+ mg	low
Editorial	Values carried forward from existing seed/DB data. Published therapeutic range is 5–50 mg (Wikidoc), placing the seed 'common' range (50–100 mg) at and above therapeutic ceiling. No controlled dose-finding studies exist. Seed values appear to reflect recreational/supratherapeutic context rather than clinical dosing. CYP2D6 phenotype creates up to 9-fold inter-individual variation in effective opioid dose (Hedenmalm 1997). Safety-critical flag: these dose values lack primary literature verification.
	ReasoningReasoning Values carried forward from existing seed/DB data. Published therapeutic range is 5–50 mg (Wikidoc), placing the seed 'common' range (50–100 mg) at and above therapeutic ceiling. No controlled dose-finding studies exist. Seed values appear to reflect recreational/supratherapeutic context rather than clinical dosing. CYP2D6 phenotype creates up to 9-fold inter-individual variation in effective opioid dose (Hedenmalm 1997). Safety-critical flag: these dose values lack primary literature verification. Evidence basis: community_consensus_large

Duration

oral

Field	Published	AI Proposed	Confidence
Onsettrace	20–45 minutes	20–45 minutes	low
Editorial	Inferred from PK data: Tmax 45 min for syrup (Aasmundstad 1995), 2.2h for tablet (ElMeshad 2020). Opioid effects depend on CYP2D6 morphine formation rate, not just parent compound absorption. Range represents syrup formulation onset; tablet onset would be longer.
	ReasoningReasoning Inferred from PK data: Tmax 45 min for syrup (Aasmundstad 1995), 2.2h for tablet (ElMeshad 2020). Opioid effects depend on CYP2D6 morphine formation rate, not just parent compound absorption. Range represents syrup formulation onset; tablet onset would be longer. Evidence basis: structural_analogy
Come uptrace	30–60 minutes	30–60 minutes	low
Editorial	Inferred from PK parameters and mu-opioid class subjective timecourse. Morphine levels build progressively as CYP2D6 conversion proceeds. No controlled subjective-effects study exists.
	ReasoningReasoning Inferred from PK parameters and mu-opioid class subjective timecourse. Morphine levels build progressively as CYP2D6 conversion proceeds. No controlled subjective-effects study exists. Evidence basis: structural_analogy
Peaktrace	1–2 hours	1–2 hours	low
Editorial	Inferred from t½ = 2h (Aasmundstad 1995) and typical mu-opioid agonist peak duration. Peak opioid effects expected around Tmax and persisting for approximately one half-life of the parent compound.
	ReasoningReasoning Inferred from t½ = 2h (Aasmundstad 1995) and typical mu-opioid agonist peak duration. Peak opioid effects expected around Tmax and persisting for approximately one half-life of the parent compound. Evidence basis: structural_analogy
Offsettrace	1–2 hours	1–2 hours	low
Editorial	Inferred from t½ = 2h and active metabolite morphine persistence. Sedation typically outlasts euphoria during the offset phase. Class-level inference from morphine/codeine.
	ReasoningReasoning Inferred from t½ = 2h and active metabolite morphine persistence. Sedation typically outlasts euphoria during the offset phase. Class-level inference from morphine/codeine. Evidence basis: structural_analogy
Totaltrace	4–5 hours	4–5 hours	medium
Editorial	Seed data value (4–5 hours oral). Consistent with parent compound t½ = 2h (Aasmundstad 1995) plus continued morphine metabolite activity. This represents subjective experience duration, not pharmacological half-life or drug test positivity window.
	ReasoningReasoning Seed data value (4–5 hours oral). Consistent with parent compound t½ = 2h (Aasmundstad 1995) plus continued morphine metabolite activity. This represents subjective experience duration, not pharmacological half-life or drug test positivity window. Evidence basis: community_consensus_large
After effectstrace	2–6 hours	2–6 hours	low
Editorial	Residual sedation and constipation expected after subjective opioid effects resolve. Opiate immunoassay remains positive 24+ hours (Popa 1998). Impairment may persist beyond subjective awareness. Class inference from morphine/codeine.
	ReasoningReasoning Residual sedation and constipation expected after subjective opioid effects resolve. Opiate immunoassay remains positive 24+ hours (Popa 1998). Impairment may persist beyond subjective awareness. Class inference from morphine/codeine. Evidence basis: structural_analogy

Safety

Toxicity Profiletrace

Field	Published	AI Proposed	Confidence
Acute	moderate	moderate	medium
Chronic	moderate	moderate	medium
Organs Affected	pulmonary, hepatic, CNS	pulmonary, hepatic, CNS	medium
Editorial	Work-notes recommend moderate for both acute and chronic, correcting the contradictory seed data. Evidence base: one fatal case report (Kintz 1994), hepatic GSH depletion in mice (Skoulis 1989), and mu-opioid class extrapolation for respiratory depression mechanism. Fatal concentration required ~9x therapeutic levels, supporting moderate rather than high acute toxicity. Chronic toxicity reflects hepatic GSH vulnerability and opioid-induced hyperalgesia risk from class inference.
	ReasoningReasoning Work-notes recommend moderate for both acute and chronic, correcting the contradictory seed data. Evidence base: one fatal case report (Kintz 1994), hepatic GSH depletion in mice (Skoulis 1989), and mu-opioid class extrapolation for respiratory depression mechanism. Fatal concentration required ~9x therapeutic levels, supporting moderate rather than high acute toxicity. Chronic toxicity reflects hepatic GSH vulnerability and opioid-induced hyperalgesia risk from class inference. Evidence basis: single_case_report

Dependence Profiletrace

Field	Published	AI Proposed	Confidence
Physical	high	high	medium
Psychological	high	high	medium
Compulsive Redosing	moderate	moderate	medium
Dose Escalation	high	high	medium
Editorial	Work-notes specify high physical and psychological dependence, moderate compulsive redosing, high dose escalation. No ethylmorphine-specific dependence studies exist; all inferred from morphine/codeine class pharmacology plus forensic abuse evidence (Kintz 1994 heroin-switching case, Jones 2008 impaired driving data).
	ReasoningReasoning Work-notes specify high physical and psychological dependence, moderate compulsive redosing, high dose escalation. No ethylmorphine-specific dependence studies exist; all inferred from morphine/codeine class pharmacology plus forensic abuse evidence (Kintz 1994 heroin-switching case, Jones 2008 impaired driving data). Evidence basis: structural_analogy

Withdrawal Profiletrace

Field	Published	AI Proposed	Confidence
Severity	moderate	moderate	low
Symptoms	Lacrimation, Rhinorrhea, Myalgia, Insomnia, Anxiety, Diarrhea, Piloerection, Autonomic instability, Restlessness, Yawning	Lacrimation, Rhinorrhea, Myalgia, Insomnia, Anxiety, Diarrhea, Piloerection, Autonomic instability, Restlessness, Yawning	low
Fatal	No	No	low
Medical Supervision	Required	Required	low
Editorial	Withdrawal characterization entirely from morphine/codeine class inference. Onset 8–24 hours (using 12h midpoint) reflects ethylmorphine t½ = 2h but active metabolite morphine persists longer. Acute phase 5–10 days from morphine class. No ethylmorphine-specific withdrawal study published.
	ReasoningReasoning Withdrawal characterization entirely from morphine/codeine class inference. Onset 8–24 hours (using 12h midpoint) reflects ethylmorphine t½ = 2h but active metabolite morphine persists longer. Acute phase 5–10 days from morphine class. No ethylmorphine-specific withdrawal study published. Evidence basis: structural_analogy

Tolerance Profiletrace

Field	Published	AI Proposed	Confidence
Buildup	moderate	moderate	low
Half-life	5 days	5 days	low
Full Reset	1.5 weeks	1.5 weeks	low
Cross-tolerances	morphine, codeine, oxycodone, hydrocodone, heroin, all mu-opioid agonists	morphine, codeine, oxycodone, hydrocodone, heroin, all mu-opioid agonists	low
Editorial	Work-notes flag tolerance timeline as unverified class estimate. Mechanism is well-established for morphine class (receptor desensitization, GRK/β-arrestin pathway). Cross-tolerances confirmed at class level. Confidence is low because no ethylmorphine-specific tolerance study exists.
	ReasoningReasoning Work-notes flag tolerance timeline as unverified class estimate. Mechanism is well-established for morphine class (receptor desensitization, GRK/β-arrestin pathway). Cross-tolerances confirmed at class level. Confidence is low because no ethylmorphine-specific tolerance study exists. Evidence basis: structural_analogy

Effects & Profile

Contraindications

Field	Published	AI Proposed	Confidence
respiratory Respiratory insufficiencytrace	absolute	absolute	high
Editorial	Documented in HandWiki and Wikidoc product information. Standard mu-opioid agonist class contraindication with direct clinical relevance to ethylmorphine via its morphine metabolite.
	ReasoningReasoning Documented in HandWiki and Wikidoc product information. Standard mu-opioid agonist class contraindication with direct clinical relevance to ethylmorphine via its morphine metabolite.
other Concurrent CNS depressant usetrace	absolute	absolute	high
Editorial	Ethanol metabolic inhibition data from Xu et al. 1997 in isolated rat hepatocytes. Pharmacodynamic synergism is class-level for all opioid–depressant combinations. Seed interaction data rates alcohol, GHB, GBL, tramadol, and ketamine as lethal.
	ReasoningReasoning Ethanol metabolic inhibition data from Xu et al. 1997 in isolated rat hepatocytes. Pharmacodynamic synergism is class-level for all opioid–depressant combinations. Seed interaction data rates alcohol, GHB, GBL, tramadol, and ketamine as lethal.
age Pediatric patients under 8 yearstrace	absolute	absolute	medium
Editorial	Wikidoc lists age contraindication. Codeine pediatric fatality analogy cited in article prose. Ethylmorphine produces more morphine per dose than codeine (7.0% vs 3.8%), potentially amplifying the UM risk.
	ReasoningReasoning Wikidoc lists age contraindication. Codeine pediatric fatality analogy cited in article prose. Ethylmorphine produces more morphine per dose than codeine (7.0% vs 3.8%), potentially amplifying the UM risk.
other Intravenous administrationtrace	absolute	absolute	medium
Editorial	Documented in Wikidoc product information. Histamine release is a known property of morphinan opioids administered intravenously, and ethylmorphine is specifically flagged for this risk.
	ReasoningReasoning Documented in Wikidoc product information. Histamine release is a known property of morphinan opioids administered intravenously, and ethylmorphine is specifically flagged for this risk.
metabolic CYP2D6 ultrarapid metabolizer statustrace	relative	relative	medium
Editorial	Inferred from codeine CYP2D6 UM pharmacogenomic data (structural analogy). Ethylmorphine's higher morphine yield vs codeine (7.0% vs 3.8%, Hedenmalm 1997) may amplify this risk. No ethylmorphine-specific UM case reports exist.
	ReasoningReasoning Inferred from codeine CYP2D6 UM pharmacogenomic data (structural analogy). Ethylmorphine's higher morphine yield vs codeine (7.0% vs 3.8%, Hedenmalm 1997) may amplify this risk. No ethylmorphine-specific UM case reports exist.
hepatic Hepatic impairmenttrace	relative	relative	medium
Editorial	GSH depletion from Skoulis 1989 (animal data). Hepatic metabolism dependence from Aasmundstad 1995 and Hedenmalm 1997 PK studies. Class-level contraindication for hepatically-metabolized opioid prodrugs.
	ReasoningReasoning GSH depletion from Skoulis 1989 (animal data). Hepatic metabolism dependence from Aasmundstad 1995 and Hedenmalm 1997 PK studies. Class-level contraindication for hepatically-metabolized opioid prodrugs.
neurological Head injury or raised intracranial pressuretrace	absolute	absolute	low
Editorial	Class-level mu-opioid agonist contraindication listed in work-notes under class-level contraindications inherited from morphine. No ethylmorphine-specific data; standard opioid prescribing guidance.
	ReasoningReasoning Class-level mu-opioid agonist contraindication listed in work-notes under class-level contraindications inherited from morphine. No ethylmorphine-specific data; standard opioid prescribing guidance.
other Paralytic ileustrace	absolute	absolute	low
Editorial	Class-level mu-opioid agonist contraindication inherited from morphine, listed in work-notes. No ethylmorphine-specific data.
	ReasoningReasoning Class-level mu-opioid agonist contraindication inherited from morphine, listed in work-notes. No ethylmorphine-specific data.

Timeline Phases

oral

Field	Published	AI Proposed	Confidence
Onsettrace	1200–2700 sec(i=0.15)	1200–2700 sec(i=0.15)	low
Editorial	Phase breakdown inferred from PK parameters (Aasmundstad 1995: Tmax 45 min syrup, t½ 2h; ElMeshad 2020: Tmax 2.2h tablet) and mu-opioid class subjective effect timecourse. Total duration of 4–5 hours from seed data is consistent with t½ = 2h plus active metabolite morphine persistence. No controlled subjective-effects timeline study exists for ethylmorphine. All phase durations are class-inferred from morphine/codeine pharmacology.
	ReasoningReasoning Phase breakdown inferred from PK parameters (Aasmundstad 1995: Tmax 45 min syrup, t½ 2h; ElMeshad 2020: Tmax 2.2h tablet) and mu-opioid class subjective effect timecourse. Total duration of 4–5 hours from seed data is consistent with t½ = 2h plus active metabolite morphine persistence. No controlled subjective-effects timeline study exists for ethylmorphine. All phase durations are class-inferred from morphine/codeine pharmacology. Evidence basis: structural_analogy
Come uptrace	1800–3600 sec(i=0.50)	1800–3600 sec(i=0.50)	low
Editorial	Phase breakdown inferred from PK parameters (Aasmundstad 1995: Tmax 45 min syrup, t½ 2h; ElMeshad 2020: Tmax 2.2h tablet) and mu-opioid class subjective effect timecourse. Total duration of 4–5 hours from seed data is consistent with t½ = 2h plus active metabolite morphine persistence. No controlled subjective-effects timeline study exists for ethylmorphine. All phase durations are class-inferred from morphine/codeine pharmacology.
	ReasoningReasoning Phase breakdown inferred from PK parameters (Aasmundstad 1995: Tmax 45 min syrup, t½ 2h; ElMeshad 2020: Tmax 2.2h tablet) and mu-opioid class subjective effect timecourse. Total duration of 4–5 hours from seed data is consistent with t½ = 2h plus active metabolite morphine persistence. No controlled subjective-effects timeline study exists for ethylmorphine. All phase durations are class-inferred from morphine/codeine pharmacology. Evidence basis: structural_analogy
Peaktrace	3600–7200 sec(i=1.00)	3600–7200 sec(i=1.00)	low
Editorial	Phase breakdown inferred from PK parameters (Aasmundstad 1995: Tmax 45 min syrup, t½ 2h; ElMeshad 2020: Tmax 2.2h tablet) and mu-opioid class subjective effect timecourse. Total duration of 4–5 hours from seed data is consistent with t½ = 2h plus active metabolite morphine persistence. No controlled subjective-effects timeline study exists for ethylmorphine. All phase durations are class-inferred from morphine/codeine pharmacology.
	ReasoningReasoning Phase breakdown inferred from PK parameters (Aasmundstad 1995: Tmax 45 min syrup, t½ 2h; ElMeshad 2020: Tmax 2.2h tablet) and mu-opioid class subjective effect timecourse. Total duration of 4–5 hours from seed data is consistent with t½ = 2h plus active metabolite morphine persistence. No controlled subjective-effects timeline study exists for ethylmorphine. All phase durations are class-inferred from morphine/codeine pharmacology. Evidence basis: structural_analogy
Resolutiontrace	3600–7200 sec(i=0.35)	3600–7200 sec(i=0.35)	low
Editorial	Phase breakdown inferred from PK parameters (Aasmundstad 1995: Tmax 45 min syrup, t½ 2h; ElMeshad 2020: Tmax 2.2h tablet) and mu-opioid class subjective effect timecourse. Total duration of 4–5 hours from seed data is consistent with t½ = 2h plus active metabolite morphine persistence. No controlled subjective-effects timeline study exists for ethylmorphine. All phase durations are class-inferred from morphine/codeine pharmacology.
	ReasoningReasoning Phase breakdown inferred from PK parameters (Aasmundstad 1995: Tmax 45 min syrup, t½ 2h; ElMeshad 2020: Tmax 2.2h tablet) and mu-opioid class subjective effect timecourse. Total duration of 4–5 hours from seed data is consistent with t½ = 2h plus active metabolite morphine persistence. No controlled subjective-effects timeline study exists for ethylmorphine. All phase durations are class-inferred from morphine/codeine pharmacology. Evidence basis: structural_analogy
Afterglowtrace	7200–21600 sec(i=0.10)	7200–21600 sec(i=0.10)	low
Editorial	Phase breakdown inferred from PK parameters (Aasmundstad 1995: Tmax 45 min syrup, t½ 2h; ElMeshad 2020: Tmax 2.2h tablet) and mu-opioid class subjective effect timecourse. Total duration of 4–5 hours from seed data is consistent with t½ = 2h plus active metabolite morphine persistence. No controlled subjective-effects timeline study exists for ethylmorphine. All phase durations are class-inferred from morphine/codeine pharmacology.
	ReasoningReasoning Phase breakdown inferred from PK parameters (Aasmundstad 1995: Tmax 45 min syrup, t½ 2h; ElMeshad 2020: Tmax 2.2h tablet) and mu-opioid class subjective effect timecourse. Total duration of 4–5 hours from seed data is consistent with t½ = 2h plus active metabolite morphine persistence. No controlled subjective-effects timeline study exists for ethylmorphine. All phase durations are class-inferred from morphine/codeine pharmacology. Evidence basis: structural_analogy

Dose Tier Summaries

thresholdtrace

low

Minimal perceptible opioid effects at this range. A faint sense of warmth and mild anxiolysis may emerge as CYP2D6 begins converting ethylmorphine to morphine, though the subjective shift is subtle and may be imperceptible in CYP2D6 poor metabolizers. Physically, slight muscle relaxation and a gentle easing of bodily tension are the most noticeable signs. No significant sedation, analgesia, or respiratory effects are expected. This range falls below the established therapeutic antitussive dose. CYP2D6 phenotype is the dominant variable at this level — an ultrarapid metabolizer may perceive mild opioid effects where a poor metabolizer notices nothing.

Editorial

Work-notes specify threshold at ~20 mg. No controlled subjective-effects studies exist for ethylmorphine at any dose. Description inferred from mu-opioid agonist class pharmacology (morphine/codeine) and the prodrug conversion kinetics described in Aasmundstad 1995 and Hedenmalm 1997.

Reasoning

Evidence basis: structural_analogy

lighttrace

low

Mild analgesia and anxiolysis become clearly perceptible. A gentle sedation settles in alongside bodily warmth and slight heaviness. Antitussive effects are present at this range, which overlaps with the lower end of therapeutic dosing. Physical effects include mild muscle relaxation, possible pupil constriction, and a subtle reduction in pain sensitivity. Nausea is uncommon but possible in opioid-naive individuals. Cognitive function remains largely intact, though slight thought deceleration may be noticed. Comparable in character to a low therapeutic dose of codeine, though ethylmorphine produces proportionally more morphine per milligram (7.0% vs 3.8%).

Editorial

Work-notes specify light at 40–50 mg. Therapeutic range per Wikidoc is 5–50 mg, placing the light tier at the upper end of therapeutic dosing. Effects inferred from morphine/codeine class and the comparative PK data (Hedenmalm 1997).

Reasoning

Evidence basis: structural_analogy

commontrace

low

Clear mu-opioid agonist effects emerge — moderate analgesia, noticeable sedation, and a warm euphoric contentment. Anxiety suppression is pronounced. Pupil constriction is visible and consistent. The antitussive ceiling is reached within this range. Bodily heaviness and muscle relaxation are prominent. Nausea is possible, particularly in opioid-naive users. Constipation onset begins. Mild respiratory slowing occurs but is typically not subjectively distressing at this level. A body high characterized by diffuse warmth and spontaneous pleasant sensations is common. Cognitive effects include thought deceleration, focus suppression, and mild motor control impairment. This range straddles the upper therapeutic boundary — doses above 50 mg exceed published therapeutic recommendations.

Editorial

Work-notes specify common at 50–100 mg. Published therapeutic range tops out at 50 mg (Wikidoc), so the upper half of this tier is supratherapeutic. Effect descriptions inferred from mu-opioid class pharmacology. The discrepancy between therapeutic and seed 'common' dose is noted per work-notes instruction.

Reasoning

Evidence basis: structural_analogy

strongtrace

low

Pronounced sedation and euphoria dominate the experience. Analgesia is substantial. Cognitive impairment becomes significant — decision-making, psychomotor coordination, and attention are markedly reduced. Emotional suppression and a sense of detached contentment are characteristic. Respiratory depression risk becomes clinically significant at this range. Nausea and vomiting are likely in non-tolerant individuals. Constipation is expected. Pupil constriction is marked. Sexual arousal suppression is typical. The body high is intense, with heavy sedation that may approach somnolence at the upper end. This range exceeds all published therapeutic dosing. Driving and machinery operation are absolutely unsafe. The risk of adverse outcomes increases substantially, particularly in CYP2D6 ultrarapid metabolizers who may experience morphine levels equivalent to a heavy dose.

Editorial

Work-notes specify strong at 100–200 mg, well above the 5–50 mg therapeutic range. All effect descriptions are class-inferred from morphine/codeine pharmacology. Respiratory depression risk escalation at supratherapeutic doses is a well-established mu-opioid class property.

Reasoning

Evidence basis: structural_analogy

heavytrace

low

This range carries severe risk of life-threatening respiratory depression. Sedation is profound and may approach or reach unconsciousness. The one published fatal ethylmorphine overdose (Kintz et al. 1994) occurred at blood concentrations consistent with doses in this range. Nausea, vomiting, and aspiration risk are high. Cardiovascular depression may occur. Complete psychomotor incapacitation is expected. The combination of respiratory depression and loss of consciousness creates extreme overdose danger, compounded by the unpredictable CYP2D6-dependent morphine formation rate. Co-ingestion of any CNS depressant at this dose level is potentially fatal. Naloxone should be immediately accessible. This range is never therapeutically indicated and represents a medical emergency threshold.

Editorial

Work-notes specify heavy at 200+ mg. Fatal case (Kintz 1994) at 488 ng/mL blood (~9x therapeutic level) provides the only direct human toxicity anchor. All other characterization is class-inferred from morphine overdose pharmacology. Approximate lethal dose of ~500 mg from Wikidoc is unverified (flagged as safety-citation-needed).

Reasoning

Evidence basis: structural_analogy

History

current version

published Oct 2, 2026system—

versions

2 total · since previous: +0 / −0 citations

publication ledger

publish Oct 2, 2026 · by agent-psx

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correction contact@psychedex.org

Sources

1 strong · 15 moderate · 4 weak

[1]
weak
Ethylmorphine
2023
linkno claims checked
[2]
moderate
Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose
Aasmundstad TA, Xu BQ, Johansson I, Ripel A, Bjørneboe A, Christophersen AS, Bodd E, Mørland J · 1995 · British Journal of Clinical Pharmacology
pubmed 7654478no claims checked
[3]
moderate
Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity
Hedenmalm K, Sundgren M, Granberg K, Spigset O, Dahlqvist R · 1997 · Therapeutic Drug Monitoring
pubmed 9421105no claims checked
[4]
weak
Ethylmorphine concentrations in human samples in an overdose case
Kintz P, Jamey C, Mangin P · 1994 · Archives of Toxicology
pubmed 8024470no claims checked
[5]
moderate
Driving under the influence of opiates: concentration relationships between morphine, codeine, 6-acetyl morphine, and ethyl morphine in blood
Jones AW, Holmgren A, Kugelberg FC · 2008 · Journal of Analytical Toxicology
pubmed 18430293no claims checked
[6]
moderate
Effects of ethanol on ethylmorphine metabolism in isolated rat hepatocytes: characterization by means of a multicompartmental model
Xu BQ, Aasmundstad TA, Lillekjendlie B, Bjørneboe A, Christophersen AS, Mørland J · 1997 · Pharmacology & Toxicology
pubmed 9140136no claims checked
[7]
weak
Ethylmorphine - Wikidoc
2022
linkno claims checked
[8]
moderate
Supercritical Fluid Chromatography—Mass Spectrometry (SFC-MS) and MALDI-TOF-MS of Heterocyclic Compounds with Trivalent and Pentavalent Nitrogen in Cough Relief Medical Forms Tuxi and Cosylan
Brondz I, Brondz A · 2012 · American Journal of Analytical Chemistry
doi.org/10.4236/ajac.2012.312a115no claims checked
[9]
moderate
Ethylmorphine — PubChem Compound CID 5359271
National Center for Biotechnology Information · 2024
linkno claims checked
[10]
moderate
Adverse effects of opioid agonists and agonist-antagonists in anaesthesia.
Bowdle TA · 1998 · Drug Safety
pubmed 9747665no claims checked
[11]
moderate
'Weak' opioid analgesics. Codeine, dihydrocodeine and tramadol: no less risky than morphine
Prescrire International · 2016 · Prescrire International
pubmed 27042732no claims checked
[12]
moderate
Inhibition by morphine and its analogs of action potentials in adult rat dorsal root ganglion neurons
Mizuta K, Fujita T, Kumamoto E · 2012 · Journal of Neuroscience Research
doi.org/10.1002/jnr.23059 pubmed 22488082no claims checked
[13]
moderate
Inhibitory effects of opioids on compound action potentials in frog sciatic nerves and their chemical structures
Mizuta K, Fujita T, Nakatsuka T, Kumamoto E · 2008 · Life Sciences
doi.org/10.1016/j.lfs.2008.06.002 pubmed 18593589no claims checked
[14]
moderate
Ethylmorphine N-demethylase activity as a marker for cytochrome P450 CYP3A activity in rat hepatic microsomes
Amacher DE, Schomaker SJ · 1998 · Toxicology Letters
pubmed 9574808no claims checked
[15]
moderate
Core in Cup Ethylmorphine Hydrochloride Tablet for Dual Fast and Sustained Pain Relief: Formulation, Characterization, and Pharmacokinetic Study
ElMeshad AN, Abdel-Haleem KM, Abdel Gawad NA, El-Nabarawi MA, Sheta NM · 2020 · AAPS PharmSciTech
doi.org/10.1208/s12249-020-01759-0 pubmed 32856114no claims checked
[16]
moderate
Morphine formation from ethylmorphine: implications for drugs-of-abuse testing in urine
Popa C, Beck O, Brodin K · 1998 · Journal of Analytical Toxicology
pubmed 9547411no claims checked
[17]
moderate
Depression of hepatic glutathione by opioid analgesic drugs in mice
Skoulis NP, James RC, Harbison RD, Roberts SM · 1989 · Toxicology and Applied Pharmacology
pubmed 2471291no claims checked
[18]
strong
GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome
Busardò FP, Jones AW · 2015 · Current Neuropharmacology
doi.org/10.2174/1570159x13666141210215423 pubmed 26074743no claims checked
[19]
weak
Lethal combination of tramadol and multiple drugs affecting serotonin
Ripple MG, Pestaner JP, Levine BS, Smialek JE · 2000 · American Journal of Forensic Medicine and Pathology
pubmed 11111800no claims checked
[20]
moderate
Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles
Roulet L, Rollason V, Desmeules J, Piguet V · 2021 · Drugs
doi.org/10.1007/s40265-021-01515-z pubmed 34196947no claims checked

Claim Verification

No claim verification has run for this version.

Coverage & Gaps

effect links

66 links · 66 approved · 0 audited0/66 with evidence basis

interactions

7 approved pairs0/7 graded

Ethylmorphine

Value Provenance

Dosing

oraltrace →

Duration

oral

Safety

Toxicity Profiletrace →

Dependence Profiletrace →

Withdrawal Profiletrace →

Tolerance Profiletrace →

Effects & Profile

Contraindications

Timeline Phases

oral

Dose Tier Summaries

History

Sources

Claim Verification

Coverage & Gaps

oraltrace

Toxicity Profiletrace

Dependence Profiletrace

Withdrawal Profiletrace

Tolerance Profiletrace